CO2023007335A2 - Ácidos pirazol piperidin carboxílicos sustituidos - Google Patents
Ácidos pirazol piperidin carboxílicos sustituidosInfo
- Publication number
- CO2023007335A2 CO2023007335A2 CONC2023/0007335A CO2023007335A CO2023007335A2 CO 2023007335 A2 CO2023007335 A2 CO 2023007335A2 CO 2023007335 A CO2023007335 A CO 2023007335A CO 2023007335 A2 CO2023007335 A2 CO 2023007335A2
- Authority
- CO
- Colombia
- Prior art keywords
- diseases
- hfref
- carboxylic acids
- heart
- disease
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000020832 chronic kidney disease Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 abstract 3
- 208000008960 Diabetic foot Diseases 0.000 abstract 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 2
- 208000019622 heart disease Diseases 0.000 abstract 2
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- KPVQNXLUPNWQHM-RBEMOOQDSA-N 3-acetylpyridine adenine dinucleotide Chemical compound CC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 KPVQNXLUPNWQHM-RBEMOOQDSA-N 0.000 abstract 1
- CANSPPZTVXEOJH-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridine-3-carboxylic acid Chemical class C1CCNC2=C1NN=C2C(=O)O CANSPPZTVXEOJH-UHFFFAOYSA-N 0.000 abstract 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000006306 Cor pulmonale Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213020 | 2020-12-10 | ||
| PCT/EP2021/084987 WO2022122914A1 (en) | 2020-12-10 | 2021-12-09 | Substituted pyrazolo piperidine carboxylic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023007335A2 true CO2023007335A2 (es) | 2023-06-09 |
Family
ID=73793025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0007335A CO2023007335A2 (es) | 2020-12-10 | 2023-06-02 | Ácidos pirazol piperidin carboxílicos sustituidos |
Country Status (31)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4011874A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
| WO2024163561A1 (en) * | 2023-01-31 | 2024-08-08 | Invivosciences, Inc. | Systems and methods for treating heart failure with preserved ejection fraction |
| WO2025067414A1 (zh) * | 2023-09-27 | 2025-04-03 | 海思科医药集团股份有限公司 | 吡唑羧酸衍生物及其在医药上的应用 |
| WO2025162280A1 (zh) * | 2024-01-30 | 2025-08-07 | 海思科医药集团股份有限公司 | 吡唑羧酸衍生物及其在医药上的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| BRPI0816382A2 (pt) * | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| UA109650C2 (xx) | 2010-02-27 | 2015-09-25 | Біс-арилзв'язані арилтриазолони та їх застосування | |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| EP2632551B1 (en) * | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| HRP20191755T1 (hr) * | 2012-09-07 | 2019-12-27 | Boehringer Ingelheim International Gmbh | Alkoksipirazoli kao aktivatori topljive gvanilat ciklaze |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| SI3215498T1 (sl) | 2014-11-03 | 2018-11-30 | Bayer Pharma Aktiengesellschaft | Hidroksialkil-substituirani derivati feniltriazola in njihove uporabe |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| CN116829545A (zh) * | 2020-12-10 | 2023-09-29 | 拜耳公司 | 取代的吡唑基哌啶羧酸 |
| AU2021398486A1 (en) * | 2020-12-10 | 2023-06-22 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
-
2021
- 2021-12-09 AR ARP210103422A patent/AR124297A1/es unknown
- 2021-12-09 RS RS20241357A patent/RS66294B1/sr unknown
- 2021-12-09 SI SI202130234T patent/SI4259617T1/sl unknown
- 2021-12-09 AU AU2021393988A patent/AU2021393988A1/en active Pending
- 2021-12-09 KR KR1020237022818A patent/KR20230118144A/ko active Pending
- 2021-12-09 PL PL21823605.7T patent/PL4259617T3/pl unknown
- 2021-12-09 WO PCT/EP2021/084987 patent/WO2022122914A1/en not_active Ceased
- 2021-12-09 LT LTEPPCT/EP2021/084987T patent/LT4259617T/lt unknown
- 2021-12-09 EP EP21823605.7A patent/EP4259617B1/en active Active
- 2021-12-09 GE GEAP202316287A patent/GEAP202316287A/en unknown
- 2021-12-09 GE GEAP202116287A patent/GEP20247649B/en unknown
- 2021-12-09 JP JP2023535063A patent/JP2023552583A/ja active Pending
- 2021-12-09 PE PE2023001808A patent/PE20231501A1/es unknown
- 2021-12-09 TW TW110146019A patent/TW202237589A/zh unknown
- 2021-12-09 DK DK21823605.7T patent/DK4259617T3/da active
- 2021-12-09 ES ES21823605T patent/ES2997117T3/es active Active
- 2021-12-09 MX MX2023006903A patent/MX2023006903A/es unknown
- 2021-12-09 HR HRP20241543TT patent/HRP20241543T1/hr unknown
- 2021-12-09 PT PT218236057T patent/PT4259617T/pt unknown
- 2021-12-09 CR CR20230242A patent/CR20230242A/es unknown
- 2021-12-09 US US18/256,647 patent/US20240051935A1/en active Pending
- 2021-12-09 IL IL303296A patent/IL303296A/en unknown
- 2021-12-09 FI FIEP21823605.7T patent/FI4259617T3/fi active
- 2021-12-09 CA CA3204495A patent/CA3204495A1/en active Pending
- 2021-12-09 CN CN202180081892.0A patent/CN116710439A/zh active Pending
- 2021-12-09 HU HUE21823605A patent/HUE069255T2/hu unknown
-
2023
- 2023-06-01 EC ECSENADI202340828A patent/ECSP23040828A/es unknown
- 2023-06-02 CO CONC2023/0007335A patent/CO2023007335A2/es unknown
- 2023-06-06 CL CL2023001632A patent/CL2023001632A1/es unknown
- 2023-06-07 SA SA523441083A patent/SA523441083B1/ar unknown
- 2023-06-07 DO DO2023000115A patent/DOP2023000115A/es unknown
- 2023-06-08 JO JOJO/P/2023/0132A patent/JOP20230132A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000115A (es) | 2023-07-16 |
| AU2021393988A1 (en) | 2023-06-22 |
| DK4259617T3 (da) | 2024-12-09 |
| CL2023001632A1 (es) | 2023-11-10 |
| LT4259617T (lt) | 2024-12-10 |
| PE20231501A1 (es) | 2023-09-26 |
| CA3204495A1 (en) | 2022-06-16 |
| GEAP202316287A (en) | 2023-09-11 |
| AU2021393988A9 (en) | 2024-09-19 |
| CN116710439A (zh) | 2023-09-05 |
| JP2023552583A (ja) | 2023-12-18 |
| PL4259617T3 (pl) | 2025-03-17 |
| GEP20247649B (en) | 2024-07-25 |
| SI4259617T1 (sl) | 2025-02-28 |
| AR124297A1 (es) | 2023-03-15 |
| HUE069255T2 (hu) | 2025-02-28 |
| EP4259617B1 (en) | 2024-10-23 |
| PT4259617T (pt) | 2024-12-05 |
| EP4259617A1 (en) | 2023-10-18 |
| ECSP23040828A (es) | 2023-07-31 |
| IL303296A (en) | 2023-07-01 |
| KR20230118144A (ko) | 2023-08-10 |
| SA523441083B1 (ar) | 2025-06-12 |
| US20240051935A1 (en) | 2024-02-15 |
| RS66294B1 (sr) | 2025-01-31 |
| HRP20241543T1 (hr) | 2025-01-03 |
| WO2022122914A1 (en) | 2022-06-16 |
| FI4259617T3 (fi) | 2024-11-27 |
| MX2023006903A (es) | 2023-06-26 |
| ES2997117T3 (en) | 2025-02-14 |
| CR20230242A (es) | 2023-07-19 |
| JOP20230132A1 (ar) | 2023-06-08 |
| TW202237589A (zh) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000115A (es) | Ácidos pirazol piperidin carboxílicos sustituidos | |
| DOP2023000114A (es) | Ácidos pirazolo piperidin carboxílicos sustituidos | |
| Giglioli et al. | Effects of ULTRAfiltration vs. DIureticS on clinical, biohumoral and haemodynamic variables in patients with deCOmpensated heart failure: the ULTRADISCO study | |
| Jia et al. | Arterial stiffness: a nexus between cardiac and renal disease | |
| MX2010000927A (es) | Uso de analogos y derivados de la vitamina k para el tratamiento de transtornos y condiciones de enfermedad en humanos. | |
| NZ715983A (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
| JP2013523152A5 (enExample) | ||
| JP2012236849A5 (enExample) | ||
| DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| UY31310A1 (es) | Ácidos 6-fenilnicotínicos sustituidos y su uso | |
| BR112022003745A2 (pt) | Proteínas de fusão terapêuticas | |
| WO2015091414A3 (de) | Substituierte piperidinyl-tetrahydrochinoline und ihre verwendung als alpha-2c adrenorezeptor antagonisten | |
| EP4488371A3 (en) | Compounds and methods for modulating angiotensinogen expression | |
| WO2008096816A1 (ja) | 血管新生誘導剤及びそれに用いられるポリペプチド | |
| MX339537B (es) | Sulodexide para uso en el tratamiento de patologias en donde estan involucradas las metalo proteinasas. | |
| Yetman | Cardiovascular pharmacotherapy in patients with Marfan syndrome | |
| WO2015175502A3 (en) | Replacement therapy for natriuretic peptide deficiencies | |
| Heerspink et al. | POS-380 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (THE ALIGN STUDY) | |
| BR112014005518A2 (pt) | 2-(cromano-6-ilóxi)-tiazóis substituídos e a utilização dos mesmos como produtos farmacêuticos | |
| ECSP22078861A (es) | Derivado de arilo o heteroarilo | |
| CR20250112A (es) | Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales | |
| Otaki et al. | Plasma thioredoxin-1 level is associated with renal tubular damage and predicts poor prognosis in patients with chronic heart failure | |
| MARKER | THE TAMILNADU Dr. MGR MEDICAL UNIVERSITY CHENNAI-600 032 | |
| Fukata et al. | Relationship of circulating coagulation/fibrinolysis and endothelium biomarkers with CHA2DS2-VASc scores in arrhythmia patients | |
| Seligman | The Post Phlebitic Syndrome: A Method of Treatment |